Nomenclature
CAS number: 144598-75-4
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4
H-pyrido[1,2-
a]pyrimidin-4-one; 9-hydroxyrisperidone; RO-76477; R-76477; Invega (J & J).
C
23H
27FN
4O
3; mol wt 426.48.
C 64.77%, H 6.38%, F 4.45%, N 13.14%, O 11.25%.
Description and references
Dual antagonist of central dopamine D2 and
serotonin type 2 (5HT2a) receptors; also active as an antagonist
at α1 and α2 adrenergic receptors and H1 histamine receptors. Major active metabolite of risperidone, q.v. Prepn: C. G.
M. Janssen et al., EP 368388; eidem, US 5158952 (1990, 1992 both to Janssen). Simultaneous LC/MS/MS
determn with risperidone in plasma: M.
Aravagiri, S. R. Marder, J. Mass Spectrom. 35, 718 (2000) DOI PubMed. Clinical trial in schizophrenia: J. Kane et al., Schizophr. Res. 90, 147 (2007) DOI PubMed. Review of development and clinical experience:
L. Citrome, Int. J. Clin. Pract. 61, 653-662 (2007) DOI PubMed.
Properties
Crystals from 2-propanol, mp 179.8°. Slightly sol in DMF; sparingly
sol in 0.1N HCl, methylene chloride. Practically insol
in water, hexane, 0.1N NaOH.Derivative
Palmitate.
Nomenclature
CAS number: 199739-10-1
Hexadecanoic acid 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4
H-pyrido[1,2-
a]pyrimidin-9-yl ester; 9-hydroxyrisperidone palmitate; RO-92670.
C
39H
57FN
4O
4; mol wt 664.89.
C 70.45%, H 8.64%, F 2.86%, N 8.43%, O 9.63%.
Description and references
Prepn: M. K. J. Franois et al., WO 9744039; eidem, US 6077843 (1997,
2000 both to Janssen).
Properties
Crystals from isopropanol.Therapeutic Category
Antipsychotic.
Keywords
Antipsychotic; Benzisoxazoles; Serotonin-Dopamine Antagonist